eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 56
Review paper

Platelets, lymphocytes and erythrocytes from Alzheimer’s disease patients: the quest for blood cell-based biomarkers

Ryszard Pluta, Marzena Ułamek-Kozioł, Sławomir Januszewski, Stanisław J. Czuczwar

Folia Neuropathol 2018; 56 (1): 14-20
Online publish date: 2018/03/28
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
In elderly population, Alzheimer’s disease is a common neurodegenerative disorder and accounts for about 70% of all cases of dementia. The neurodegenerative processes of this disease start presumably 20 years ahead of the clinical beginning of the disorder. The postmortem histopathological examination, brains from Alzheimer’s disease patients with characteristic features like amyloid plaques and neurofibrillary tangles, neuronal and synaptic disintegration confirm the final diagnosis of Alzheimer’s disease. Senile plaques are composed of -amyloid peptide, deriving from the amyloid protein precursor, which is present not only in the brain tissue, but also in other non-neuronal tissues. Some investigations reported that platelets possess amyloid protein precursor and all the enzymatic activities required for the metabolism of this protein throughout the same pathways present in the brain. Thus, platelets may be a good peripheral blood cell-based biomarker to study the onset of Alzheimer’s disease. Another line of research indicated molecular and cellular aberrations in blood lymphocytes and erythrocytes from Alzheimer’s disease patients and emphasizes the systemic nature of the disease. In this review, we will summarize the recent knowledge on the involvement and/or response of platelets, lymphocytes and red blood cells in the circulation during Alzheimer’s disease development. The facts will be reviewed with the special possibility for applying the above blood cells as Alzheimer’s disease preclinical and antemortem blood cell-based biomarkers.

Alzheimer’s disease, amyloid, diagnostic, blood cell-based biomarkers, platelets, lymphocytes, erythrocytes

Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leone MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement 2015; 11: 58-69.
Bulati M, Buffa S, Martorana A, Gervasi F, Camarda C, Azzarello DM, Monastero R, Caruso C, Colonna-Romano G. Double negative (IgG+IgDCD27–) B cells are increased in a cohort of moderate-severe Alzheimer’s disease patients and show a proinflammatory trafficking receptor phenotype. J Alzheimer’s Dis 2015; 44: 1241-1251.
Canobbio I, Abubaker AA, Visconte C, Torti M, Pula G. Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer’s disease. Front Cell Neurosci 2015; 9: 65.
Carelli-Alinovi C, Ficarra S, Russo AM, Giunta E, Barreca D, Gal­tieri A, Misiti F, Tellone E. Involvement of acetylcholinesterase and protein kinase C in the protective effect of caffeine against -amyloid-induced alterations in red blood cells. Biochimie 2016; 121: 52-59.
Catricala S, Torti M, Ricevuti G. Alzheimer disease and platelets: how’s that relevant. Immun Ageing 2012; 9: 20.
Da Mesquita SA, Ferreira C, Sousa JC, Correia-Neves M, Sousa N, Marques F. Insights on the pathophysiology of Alzheimer’s disease: the crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neurosci Biobehav Rev 2016; 68: 547-562.
Deardorff WJ, Grossberg GT. Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics. Expert Rev Neurother 2017; 17: 17-32.
Farıas G, Perez P, Slachevsky A, Maccioni RB. Platelet tau pattern correlates with cognitive status in Alzheimer’s disease. J Alzheimer’s Dis 2012; 31: 65-69.
Giubilei F, Antonini G, Montesperelli C, Sepe-Monti M, Cannoni S, Pichi A, Tisei P, Casini AR, Buttinelli C, Prencipe M, Salvetti M,
Ristori G. T cell response to amyloid- and to mitochondrial antigens in Alzheimer’s disease. Dement Geriatr Cogn Disord 2003; 16: 35-38.
Gowert NS, Donner L, Chatterjee M, Eisele YS, Towhid ST, Münzer P, Walker B, Ogorek I, Borst O, Grandoch M, Schaller M, Fischer JW, Gawaz M, Weggen S, Lang F, Jucker M, Elvers M. Blood platelets in the progression of Alzheimer’s disease. PLoS One 2014; 9: e90523.
Heneka TM, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015; 14: 388-405.
Kiko T, Nakagawa K, Satoh A, Tsuduki T, Furukawa K, Arai H, Miyazawa T. Amyloid beta levels in human red blood cells. PLoS One 2012; 7: e49620.
Kocki J, Ułamek-Kozioł M, Bogucka-Kocka A, Januszewski S, Jabłoński M, Gil-Kulik P, Brzozowska J, Petniak A, Furmaga- Jabłońska W, Bogucki J, Czuczwar SJ, Pluta R. Dysregulation of amyloid- protein precursor, -secretase, presenilin 1 and 2 genes in the rat selectively vulnerable CA1 subfield of hippocampus following transient global brain ischemia. J Alzheimer’s Dis 2015; 47: 1047-1056.
Kosenko EA, Aliev G, Kaminsky YG. Relationship between chronic disturbance of 2,3-diphosphoglycerate metabolism in erythrocytes and Alzheimer disease. CNS Neurol Disord Drug Targets 2016; 15: 113-123.
Kucheryavykh LY, Dávila-Rodríguez J, Rivera-Aponte DE, Zueva LV, Washington AV, Sanabria P, Inyushin MY. Platelets are responsible for the accumulation of beta-amyloid in blood clots inside and around blood vessels in mouse brain after thrombosis. Brain Res Bull 2017; 128: 98-105.
Kuhla A, Ludwig SC, Kuhla B, Münch G, Vollmar B. Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer’s disease brain. Neurobiol Aging 2015; 36: 753-761.
Licastro F, Porcellini E. Persistent infections, immune-senescence and Alzheimer’s disease. Oncoscience 2016; 3: 135-142.
Lueg G, Gross CC, Lohmann H, Johnen A, Kemmling A, Deppe M, Groger J, Minnerup J, Wiendl H, Meuth SG, Duning T. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer’s disease. Neurobiol Aging 2015; 36: 81-89.
Martorana A, Bulati M, Buffa S, Pellicanò M, Caruso C, Candore G, Colonna-Romano G. Immunosenescence, inflammation and Alzheimer’s disease. Longev Healthspan 2012; 1: 8.
Mietelska-Porowska A, Wojda U. T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer’s disease: Potential pools of new biomarkers. J Immunol Res 2017; 2017: 17.
Mota SI, Costa RO, Ferreira IL, Santana I, Caldeira GL, Padovano C, Fonseca AC, Baldeiras I, Cunha C, Letra L, Oliveira CR, Pereira CM, Rego AC. Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer’s disease. Biochim Biophys Acta 2015; 1852: 1428-1441.
Nakagawa K, Kiko T, Kuriwada S, Miyazawa T, Kimura F, Miyazawa T. Amyloid induces adhesion of erythrocytes to endothelial cells and affects endothelial viability and functionality. Biosci Biotechnol Biochem 2011; 75: 2030-2033.
Nakagawa K, Kiko T, Miyazawa T, Sookwong P, Tsuduki T, Satoh A, Miyazawa T. Amyloid -induced erythrocytic damage and its attenuation by carotenoids. FEBS Lett 2011; 585: 1249-1254.
Nesteruk M, Nesteruk T, Styczyńska M,Mandecka M, Barczak A, Barcikowska M. Combined use of biochemical and volumetric biomarkers to assess the risk of conversion of mild cognitive impairment to Alzheimer’s disease. Folia Neuropathol 2016; 54: 369-374.
Neumann K, Farias G, Slachevsky A, Perez P, Maccioni RB. Human platelet tau: A potential peripheral marker for Alzheimer’s disease. J Alzheimer’s Dis 2011; 25: 103-109.
Pluta R, Ułamek M, Jabłoński M. Alzheimer’s mechanisms in ischemic brain degeneration. Anat Rec 2009; 292: 1863-1881.
Pluta R, Furmaga-Jabłońska W, Maciejewski R, Ułamek-Kozioł M, Jabłoński M. Brain ischemia activates beta- and gamma-secretase cleavage of amyloid precursor protein: significance in sporadic Alzheimer’s disease. Mol Neurobiol 2013; 47: 425-434.
Pluta R, Jabłoński M, Ułamek-Kozioł M, Kocki J, Brzozowska J, Januszewski S, Furmaga-Jabłońska W, Bogucka-Kocka A, Maciejewski R, Czuczwar SJ. Sporadic Alzheimer’sdisease begins as episodes of brain ischemia and ischemically dysregulated Alzheimer’s disease genes. Mol Neurobiol 2013; 48: 500-515.
Pluta R, Kocki J, Ułamek-Kozioł M, Petniak A, Gil-Kulik P, Januszewski S, Bogucki J, Jabłoński M, Brzozowska J, Furmaga-Jabłońska W, Bogucka-Kocka A, Czuczwar SJ. Discrepancy in expression of-secretase and amyloid- protein precursor in Alzheimer-related genes in the rat medial temporal lobe cortex following transient global brain ischemia. J Alzheimers Dis 2016; 51: 1023-1031.
Pluta R, Kocki J, Ułamek-Kozioł M, Bogucka-Kocka A, Gil-Kulik P, Januszewski S Jabłoński M, Petniak A, Brzozowska J, Bogucki J, Furmaga-Jabłońska W, Czuczwar SJ. Alzheimer-associated presenilin 2 gene is dysregulated in rat medial temporal lobe cortex after complete brain ischemia due to cardiac arrest. Pharmacol Rep 2016; 68: 155-161.
Prodan CI, Szasz R, Vincent AS, Ross ED, Dale GL. Coated platelets retain amyloid precursor protein on their surface. Platelets 2006; 17: 56-60.
Prodan CI, Ross ED, Vincent AS, Dale GL. Rate of progression in Alzheimer’s disease correlates with coated-platelet levels – a longitudinal study. Transl Res 2008; 152: 99-102.
Richartz-Salzburger E, Batra A, Stransky E, Laske C, Köhler N, Bartels M, Buchkremer G, Schott K. Altered lymphocyte distribution in Alzheimer’s disease. J Psychiatr Res 2007; 41: 174-178.
Sakurai H, Hanyu H, Sato T, Kume K, Hirao K, Kanetaka H, Iwamoto T. Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot study. Geriatr Gerontol Int 2013; 13: 90-97.
Schuchardt JP, Köbe T, Witte V, Willers J, Gingrich A, Tesky V, Pantel J, Rujescu D, Illig T, Flöel A, Hahn A. Genetic variants of the FADS gene cluster are associated with erythrocyte membrane LC PUFA levels in patients with mild cognitive impairment. J Nutr Health Aging 2016; 20: 611-620.
Schwartz M, Deczkowska A. Neurological disease as a failure of brain-immune crosstalk: the multiple faces of neuroinflammation. Trends Immunol 2016; 37: 668-679.
Slachevsky A, Guzman-Martınez L, Delgado C, Reyes P, Farıas GA, Munoz-Neira C, Bravo E, Farıas M, Flores P, Garrido C, Becker JT, Lopez OL, Maccioni RB. Tau platelets correlate with regional brain atrophy in patients with Alzheimer’s disease. J Alzheimer’s Dis 2017; 55: 1595-1603.
Stevenson A, Lopez D, Khoo P, Kalaria RN, Mukaetova-Ladinska EB. Exploring erythrocytes as blood biomarkers for Alzheimer’s disease. J Alzheimers Dis 2017; 60: 845-857.
Ułamek-Kozioł M, Kocki J, Bogucka-Kocka A, Petniak A, Gil-Kulik P, Januszewski S, Bogucki J, Jabłoński M, Furmaga-Jabłońska W, Brzozowska J, Czuczwar SJ, Pluta R. Dysregulation of autophagy, mitophagy and apoptotic genes in the medial temporal lobe cortex in an ischemic model of Alzheimer’s disease. J Alzheimers Dis 2016; 54: 113-121.
Ułamek-Kozioł M, Kocki J, Bogucka-Kocka A, Januszewski S, Bogucki J, Czuczwar SJ, Pluta R. Autophagy, mitophagy and apoptotic gene changes in the hippocampal CA1 area in a rat ischemic model of Alzheimer’s disease. Pharmacol Rep 2017; 69: 1289-1294.
Veitinger M, Varga B, Guterres SB, Zellner M. Platelets, a reliable source for peripheral Alzheimer’s disease biomarkers? Acta Neuropathol Commun 2014; 2: 65.
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. Lancet Neurol 2013; 12: 357-367.
Wojda U. Alzheimer’s disease lymphocytes: potential for biomarkers? Biomark Med 2016; 10: 1-4.
Wojsiat J, Prandelli C, Laskowska-Kaszub K, Martín Requero A, Wojda U. Oxidative stress and aberrant cell cycle in Alzheimer’s disease lymphocytes: diagnostic prospects. J Alzheimer’s Dis 2015; 46: 329-350.
Wojsiat J, Laskowska-Kaszub K, Mietelska-Porowska A, Wojda U. Search for Alzheimer’s disease biomarkers in blood cells: hypo­theses-driven approach. Biomark Med 2017; 11: 917-931.
Zhang J, Kong Q, Zhang Z, Ge P, Ba D, He W. Telomere dysfunction of lymphocytes in patients with Alzheimer disease. Cogn Behav Neurol 2003; 16: 170-176.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe